TAK 259 |
| رقم الكتالوجGB40382 |
Novel, selective, and orally active α1D adrenoceptor antagonist (Ki value 1.1 nM, and 200-800 fold selective over α1A and α1B, respectively) with anti-urinary frequency effects: reducing human Ether-a-go-go-Related Gene (hERG) liabilities. Clinical candidate, and a promising novel therapeutic agent for the treatment of OAB (overactive bladder) symptoms.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1192347-42-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Novel, selective, and orally active α1D adrenoceptor antagonist (Ki value 1.1 nM, and 200-800 fold selective over α1A and α1B, respectively) with anti-urinary frequency effects: reducing human Ether-a-go-go-Related Gene (hERG) liabilities. Clinical candidate, and a promising novel therapeutic agent for the treatment of OAB (overactive bladder) symptoms.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *